Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2019

Open Access 01.12.2019 | Research

Comparison of efficacy of robotic surgery, laparoscopy, and laparotomy in the treatment of ovarian cancer: a meta-analysis

verfasst von: Can Shi, Yingchun Gao, Yijun Yang, Lei Zhang, Juanpeng Yu, Ting Zhang

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2019

Abstract

Background

We intended to compare the clinical effect of robotic surgery with laparoscopy and laparotomy in ovarian cancer treatment.

Methods

The included studies were retrieved from PubMed, Embase, and the Cochrane Library databases. The Methodological Index for Nonrandomized Studies (MINORS) was used to evaluate the study quality. Effect measures were presented with weighted mean difference (WMD)/odds ratio (OR) and 95% confidence interval (CI), and heterogeneity test was assessed using Q test and I2 statistics to determine the use of the random effects model or fixed effects model. Egger’s test was used to assess the publication bias.

Results

A total of eight studies was included in this meta-analysis with a MINORS score of 16–18. In the random effects model, estimated blood loss (EBL) of robotic surgery was significantly less compared with laparotomy (WMD = − 521.7027, 95% CI − 809.7816; − 233.6238). In the fixed effects model, length of hospital stay (LHS) (WMD = − 5.2225, 95% CI − 6.1485; − 4.2965) and postoperative complication (PC) (OR = 0.4710, 95% CI 0.2537; 0.8747) of robotic surgery were significantly less, and overall survival (OS) rate (OR = 6.4355, 95% CI 1.6722; 24.7678, P = 0.0070) of robotic surgery was significantly higher compared with laparotomy. There was no difference in the effect size of all variables between robotic surgery and laparoscopy. Meanwhile, a publication bias (t = 6.8290, P = 0.002405) was only identified for PC in robotic surgery and laparotomy groups; no publication bias was identified for the other variables.

Conclusions

Despite the above results, it failed to show oncological safety and recurrence by pathological stages or histologic types in this meta-analysis, and those confounding factors might affect the clinical outcome. Future meta-analyses with a larger number of eligible randomized controlled trial studies were needed to determine the most suitable treatment method for patients with different stages and types of ovarian cancer.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12957-019-1702-9) contains supplementary material, which is available to authorized users.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BMI
Body mass index
CI
Confidence interval
DFS
Disease-free survival
EBL
Estimated blood loss
LHS
Length of hospital stay
MINORS
Methodological Index for Nonrandomized Studies
OR
Odds ratio
OS
Overall survival
OT
Operating time
PC
Postoperative complication
PN
Pelvic nodes
PR
Postoperative recurrence
WMD
Weighted mean difference

Background

Ovarian cancer is one of the most common gynecological carcinomas with high fatality and recurrence rate [1]. The early diagnosis of ovarian cancer is extremely difficult due to locating deep in the pelvic cavity and lacking of typical symptoms, and most patients are preliminarily diagnosed as advanced stage with a bad prognosis and 5-year survival rate [2]. The basic treatment of ovarian cancer is still the traditional radical surgery combined with adjuvant chemotherapy. The surgery is performed to obtain a pathological diagnosis and to resect tumor tissue [3, 4].
With the development of minimally invasive surgery, the reports for laparoscopic surgery in ovarian cancer present an increasing trend. Laparoscopy provides an intuitive examination into the pelvic and abdominal organs, which is as effective as traditional laparotomy for the diagnosis of ovarian cancer with avoiding unnecessary laparotomy [5, 6]. The laparoscopy staging is an exact staging method of ovarian cancer with lesser complications and shorter hospital stay compared with laparotomy [7]. Laparoscopy provides multiple advantages in the treatment of early ovarian cancer, such as minimal abdominal incision and a decrease of recovery time. Meanwhile, there remain some disadvantages for laparoscopy in the treatment of early ovarian cancer, including preventing palpation of lymph nodes and existing a possible risk of trocar site metastasis [8].
Robotic surgery is an emerging technology in minimally invasive surgery, which overcomes some barriers of traditional laparotomy and laparoscopy. Such as, it provides three-dimensional (3-D) visualization instead of two-dimensional (2-D) visualization in laparoscopy; it remains stable and tireless which avoids the doctor’s physiologic tremor and fatigue in laparotomy; in addition, it enhances dexterity, degree of freedom, and instrument motion [9]. Based on the multiple advantages, robotic surgery presents an ever-increasing trend in gynecological oncology. Reportedly, compared with traditional laparotomy and laparoscopy, the robot surgery is viable and secure in cervical cancer therapy with less bleeding and complication as well as shorter recovery time [10]. Robotic system is secure and effective in gynecology and gynecological oncology, and it may be more fit for operating in confined spaces with difficult access, like pelvic cavity [11]. A previous review has reported that robotic surgery is expected to turn into the preferred surgical method in gynecological oncology, but it still needs to be confirmed by the results of comparing with traditional laparotomy and laparoscopy [12]. In the current study, a meta-analysis was performed to compare the effect of robotic surgery, laparoscopy, and laparotomy in the treatment of ovarian cancer, which was expected to confirm the clinical value of robotic surgery.

Methods

This meta-analysis was carried out in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines [13].

Search strategy

The relevant clinical studies were retrieved from the PubMed (http://​www.​ncbi.​nlm.​nih.​gov/​pubmed), Embase (http://​www.​embase.​com), and the Cochrane Library (http://​www.​cochranelibrary.​com) databases with search terms as “Robot*” OR “Da Vinci” OR “Leonardo's” AND “ovarian cancer” OR “oophoroma” OR “carcinoma of ovary” OR “ovarian carcinoma” OR “ovary cancer” AND “Laparoscopy” OR “laparoscopic” OR “laparotomy” OR “Open surgery” (up to November 15, 2018). The detailed retrieval strategies from PubMed are shown in Additional file 1: Table S1.

Inclusion and exclusion criteria

The literature screening was performed by two investigators, and the disagreements were settled by discussing with the third investigator. The literatures were selected with the following criteria: all the patients were women with ovarian cancer; the studies contained the robotic surgery group (patients with robotic surgery treatment) and the control group (patients with laparoscopy or laparotomy treatment), and the outcomes included overall survival (OS) rate, disease-free survival (DFS) rate, estimated blood loss (EBL)/ml, length of hospital stay (LHS)/days, operating time (OT)/min, postoperative complication (PC), pelvic nodes (PN), and postoperative recurrence (PR) or included at least one of them; the patients with or without neoadjuvant chemotherapy were all included; the types and language for the studies had no restriction. Meanwhile, the literatures with the following criteria were excluded: (1) data were incomplete and could not be used for statistical analysis; (2) studies were reviews, letters, and comments, etc.; (3) among repeated studies or multiple studies involving the same data, only the latest or the one with the most detailed information was selected; (4) there were less than five patients in each group.

Data extraction and quality evaluation

The data extraction and quality evaluation were also carried out by two investigators, and the disagreements were settled by discussing with the third investigator. The extracted information in each study included first author’s name, year of publication, study time, area and type, follow-up time, stage of ovarian cancer, the number of patients, age, body mass index (BMI), and the outcomes (including EBL, LHS, OT, PC, PN, and PR). The Methodological Index for Nonrandomized Studies (MINORS) [14] was used to conduct the quality evaluation for the studies, and the MINORS contained 12 items, such as a clearly stated aim, inclusion of consecutive patients, prospective collection of data, and endpoints appropriate to the aim of the study. Each item was scored from 0 to 2, and the total score was 24. The items with score = 0 represented that the study was not reported, and the items with score = 1 indicated that the study was reported with insufficient information, and the items with score = 2 indicted that the study was reported with sufficient information.

Statistical analysis

The R 3.12 software (R Foundation for Statistical Computing, Beijing, China, “meta” package) was used to carry out the meta-analysis, and the effect measures were presented with weighted mean difference (WMD)/odds ratio (OR) and 95% confidence interval (CI) [15]. Heterogeneity between studies was assessed using Q test [16] and I2 statistics [17], and P < 0.05 or I2 > 50% were regarded as statistically significant. The random effects model was used to pool the estimates when there was a significant heterogeneity between studies; otherwise, the fixed effects model was selected. The Egger’s test [18] was utilized to evaluate the publication bias. In addition, the sensitivity analysis was performed by comparing the pooled WMD/OR values and their 95% CI in random effects model and the fixed effects model, and the consistent estimates in the two models indicated the stable conclusions.

Results

Study retrieval

In all, 139 studies were retrieved from the PubMed, Embase, and Cochrane library databases based on the predefined search strategy, and 23 studies were retained after removal of 43 repeated studies, 10 reviews, 11 conference reports, 21 case reports/series, 17 non-human studies, and 14 irrelevant studies. Then, 15 studies were excluded according to full-text reading, including 8 studies about single-arm, 2 studies involving the same data, and 5 studies without available statistical data. Finally, 8 studies [1926] were selected and performed the following meta-analysis. The detailed filtering process is shown in Fig. 1.

Characteristics of studies

A total of 647 patients with ovarian cancer were registered in the eight included studies, including 207 patients with robotic surgery treatment and 166 patients and 274 patients with laparoscopy and laparotomy treatment, respectively. The detailed characteristics of the 8 included studies are shown in Table 1. All the studies were carried out in Italy, China, the USA, or Taiwan from 2005 to 2016 and published during a period from 2011 to 2017. The study type was non-randomized clinical study, and the duration of follow-up was 12–54 months. Most patients were middle-aged and elderly with an average age among 43–67 years and suffered an early stage of ovarian cancer. In the study of Feuer et al., there are 52% and 15% patients in the R group and O group accepting neoadjuvant chemotherapy, respectively. In the study of Ye et al., there are 2 patients accepting neoadjuvant chemotherapy, and there is no relevant information in other studies. The average BMI value was between 22.3 and 28.2, and there was no difference between groups in each study. The outcome variables (EBL, LHS, OT, PC, PN, and PR) in the eight studies are shown in Table 2.
Table 1
Characteristics of included literature
Author
Public year
Study year
Location
Stage
Type of tumor
Residual disease #
Group
N
Age, years*
BMI (kg/m2)*
Follow-up, months
Ye et al. [26]
2017
2014.11–2015.11
China
I
NA
NA
R
9
45.7 ± 13.8
24.4 ± 4.4
12–24
L
10
NA
NA
12–24
O
8
NA
NA
12–24
Gallotta et al. [23]
2016
2014.10–2016.4
Italy
IA–IIIB
NA
NA
R
32
49 (32–76)
24 (17–54)
Median 38
L
64
49 (27–73)
24 (19–41)
Median 38
Bellia et al. [19]
2016
2006–2014
France, Italy
IA–IIIC
Epithelial
NA
R
16
47.3 ± 12.3
22.3 ± 2.9
21.2 ± 12.7
L
23
49.4 ± 15.9
25.8 ± 6.5
18.5 ± 8.6
Chen et al. [21]
2015
2007.9–2015.2
Taiwan
Recurrent
NA
NA
R
8
56.3 ± 12.4
25.9 ± 5.6
NA
L
12
NA
O
15
NA
Magrina et al. [24]
2011
2004.3–2008.12
USA
I–IV
Epithelial
21
R
25
65 (23–82)
25.1 (18.7–35.8)
30
25
L
27
59 (3–85)
23.7 (17.6–37.7)
54
67
O
119
67 (19–90)
24.9 (16.6–38.5)
42
Feuer et al. [22]
2013
2008–2012
USA
I–IV
Epithelial
46
R
63
59.8 ± 11.8
27.1 ± 7.3
15.5 ± 12.3
13
O
26
55.7 ± 11.7
28.2 ± 6.1
23.5 ± 14.0
Magrina et al. [25]
2013
2006.1–2010.12
USA
Recurrent
NA
7
R
10
66.0 (45.0–83.0)
22.6 (19.7–25.5)
NA
8
L
9
57.0 (45.0–74.0)
24.5 (19.9–2.7)
NA
24
O
33
62.0 (39.0–80.0)
25.9 (18.5–41.2)
NA
Chen et al. [20]
2016
2005–2014.
Taiwan
IA–IIIC
Epithelial
44
R
44
44.3 ± 12.3
22.3 ± 2.7
13.1 ± 5.3
21
L
21
43.8 ± 10.3
24.1 ± 4.9
29.6 ± 19.0
72
O
73
49.2 ± 12.8
22.9 ± 4.2
26.7 ± 17.7
R robot, L laparoscopic, O laparotomy, BMI body mass index, NOS Newcastle-Ottawa Scale, NA data are not available
#Number of complete debulking
*Mean ± SD/median (range)
Table 2
Distribution of extracted data
Author
Year
Group
N
EBL, ml*
LHS, days*
OT, min*
PC
PN*
PR
OS rate
DFS rate
Ye et al. [26]
2017
R
9
208.9 ± 202.7
11.1 ± 3.5
251.4 ± 58.7
0
27.8 ± 8.9
NA
NA
NA
L
10
179.0 ± 234.0
15.8 ± 6.6
233.5 ± 75.9
1
27.3 ± 9.4
NA
NA
NA
O
8
375.0 ± 353.6
13.1 ± 4.6
226.0 ± 69.8
2
25.6 ± 7.0
NA
NA
NA
Gallotta et al. [23]
2016
R
32
NA
NA
NA
1
NA
NA
NA
NA
L
64
NA
NA
NA
4
NA
NA
NA
NA
Bellia et al. [19]
2016
R
16
NA
NA
270 ± 72
4
NA
1
16
15
L
23
NA
NA
288 ± 88
3
NA
2
22
21
Chen et al. [21]
2015
R
8
68.7 ± 53
4.8 ± 2.7
NA
1
NA
NA
NA
NA
L
12
95.8 ± 45
8.4 ± 8.2
NA
1
NA
NA
NA
NA
O
15
256.4 ± 258.5
16.2 ± 16.8
NA
6
NA
NA
NA
NA
Magrina et al. [24]
2011
R
25
164 ± 113
4 ± 3
315 ± 102
6
11.7 ± 6.9
NA
NA
NA
L
27
267 ± 300
3 ± 2
254 ± 83
1
13.9 ± 4.9
NA
NA
NA
O
119
1307 ± 1060
9 ± 7
261 ± 77
40
13.6 ± 7.1
NA
NA
NA
Feuer et al. [22]
2013
R
63
94.9 ± 72.9
2.3 ± 3.0
138.6 ± 38.7
10
13.3 ± 7.9
15
60
NA
O
26
385.4 ± 219.4
6.2 ± 4.9
95.2 ± 31.3
6
10.7 ± 6.8
5
19
NA
Magrina et al. [25]
2013
R
10
206.3 ± 249.9
3.4 ± 2.37
220.6 ± 113.6
2
NA
1
NA
NA
L
9
127.8 ± 153.8
4.1 ± 5.82
222.3 ± 100.1
3
NA
5
NA
NA
O
33
936.7 ± 824.8
9.9 ± 8.11
177.0 ± 95.8
14
NA
10
NA
NA
Chen et al. [20]
2016
R
44
96.9 ± 83.2
3.5 ± 1.9
176.8 ± 54.3
0
24.2 ± 13.3
NA
44
43
L
21
326.2 ± 368.7
5.5 ± 3.0
232.3 ± 85.4
0
21.4 ± 7.1
NA
21
20
O
73
848.6 ± 666.9
9.7 ± 6.4
287.2 ± 144.0
2
25.9 ± 13.2
NA
70
65
R robot, L laparoscopic, O laparotomy, EBL estimated blood loss, LHS length of hospital stay, OT operating time, PC postoperative complication, PN pelvic nodes, PR postoperative recurrence, OS overall survival, DFS disease-free survival, NA data are not available
*Mean ± SD

Quality evaluation

The methodological quality of the eight studies was assessed by MINORS, and the scores are presented in Table 3. It could be seen that the MINORS scores of the eight studies were among 16 to 18. Items such as prospective collection of data, unbiased assessment of the study endpoint, and prospective calculation of the study size were not involved in all the eight studies, and other items involving most of the eight studies were scored 2, which indicated a good quality.
Table 3
Results of quality evaluation using Methodological Index for Nonrandomized Studies (MINORS)
Author
Public year
A
B
C
D
E
F
G
H
I
J
K
L
Total scores
Ye et al. [26]
2017
2
2
0
2
0
2
2
0
2
2
2
2
18
Gallotta et al. [23]
2016
2
2
0
2
0
2
2
0
2
2
2
2
18
Bellia et al. [19]
2016
2
2
0
2
0
2
2
0
2
2
0
2
16
Chen et al. [21]
2015
2
2
0
2
0
1
2
0
2
2
2
2
17
Magrina et al. [24]
2011
2
2
0
2
0
2
2
0
2
2
2
2
18
Feuer et al. [22]
2013
2
2
0
2
0
2
2
0
2
2
1
2
17
Magrina et al. [25]
2013
2
2
0
2
0
1
2
0
2
2
2
2
17
Chen et al. [20]
2016
2
2
0
2
0
2
2
0
2
2
1
2
17
A a clearly stated aim, B inclusion of consecutive patients, C prospective collection of data, D endpoints appropriate to the aim of the study, E unbiased assessment of the study endpoint, F follow-up period appropriate to the aim of the study, G loss to follow-up less than 5%, H prospective calculation of the study size, I an adequate control group, J contemporary groups, K baseline equivalence of groups, L adequate statistical analyses

Meta-analysis

Comparison of robotic surgery and laparoscopy

Five studies reported the variable EBL of the robotic surgery group and laparoscopy group, and there was a significant heterogeneity between studies (P = 0.07, I2 = 54.7%). Similarly, there was a remarkable heterogeneity between studies for the variables LHS (P = 0.01, I2 = 69.4%) and OT (P < 0.01, I2 = 70.2%). Hence, the random effects model was selected to assess the effect size of EBL, LHS, and OT. Meanwhile, there was no obvious heterogeneity between studies for the variables OS rate, DFS rate, PC, PN and PR, and the fixed effects model was selected.
The results of the pooled estimate for each variable are shown in Table 4. It could be seen that there was no significant difference among the robotic surgery and laparoscopy groups for all variables EBL (WMD = − 55.0871, 95% CI − 139.0087; 28.8345, P = 0.1983), LHS (WMD = − 1.4296, 95% CI − 3.5326, 0.6734, P = 0.1827), OT (WMD = − 0.856, 95% CI − 46.3735; 44.6612, P = 0.9706), PC (OR = 1.454, 95% CI 0.6502; 3.2516, P = 0.3619), PN (WMD = − 0.5664, 95% CI − 3.1615; 2.0288, P = 0.6688), PR (OR = 0.2387, 95% CI 0.0445; 1.2792, P = 0.0944), OS rate (OR = 2.2000, 95% CI 0.0842; 57.4835, P = 0.6360), and DFS rate (OR = 1.6909, 95% CI 0.2572; 11.1175, P = 0.5850). The results indicated the same effect of robotic surgery and laparoscopy in the treatment of ovarian cancer (Fig. 2).
Table 4
Results of the meta-analysis
Variable
Sample size
Test of association
Model
Test of heterogeneitya,b
Egger’s testc
N1
N2
WMD/OR (95% CI)
Z
P
Q
P
I2 (%)
t
P
R vs. L
           
EBL
96
79
− 55.0871 [− 139.0087; 28.8345]
1.29
0.1983
R
8.83
0.07
54.7
0.3887
0.7234
LHS
96
79
− 1.4296[− 3.5326; 0.6734]
1.33
0.1827
R
13.06
0.01
69.4
0.9334
0.4195
OT
104
90
− 0.8561[− 46.3735; 44.6612]
0.04
0.9706
R
13.4
< 0.01
70.2
0.7602
0.5024
PC
144
166
1.4541 [0.6502; 3.2516]
0.91
0.3619
F
5.34
0.38
6.3
1.5330
0.2001
PN
78
58
− 0.5664 [− 3.1615; 2.0288]
0.43
0.6688
F
2.78
0.25
28.2
0.7882
0.5751
PR
26
32
0.2387 [0.0445; 1.2792]
1.67
0.0944
F
1.34
0.25
25.5
NA
NA
OS rate
60
44
2.2000 [0.0842; 57.4835]
0.47
0.6360
NA
NA
NA
NA
NA
NA
DFS rate
60
44
1.6909 [0.2572; 11.1175]
0.55
0.5850
F
0.05
0.83
0.0
NA
NA
R vs. O
           
EBL
125
274
− 521.7027 [− 809.7816; − 233.6238]
3.55
0.0004
R
82.54
< 0.01
93.9
1.1403
0.3178
LHS
159
274
− 5.2225 [− 6.1485; − 4.2965]
11.05
< 0.0001
F
8.36
0.14
40.2
0.1786
0.8669
OT
151
259
9.8527 [− 57.0904; 76.7958]
0.29
0.7730
R
59.75
< 0.01
93.3
0.5645
0.6119
PC
159
274
0.4710 [0.2537; 0.8747]
2.38
0.0171
F
1.77
0.88
0.0
6.8290
0.0024
PN
141
226
0.0048 [− 1.9418; 1.9514]
<0.01
0.9962
F
4.77
0.19
37.1
0.2131
0.8510
PR
73
59
0.8506 [0.3356; 2.1562]
0.34
0.7332
F
1.71
0.19
41.7
NA
NA
OS rate
107
99
6.4355 [1.6722; 24.7678]
2.71
0.0070
F
0.09
0.76
0.0
NA
NA
WMD weighted mean difference, OR odds ratio, CI confidence interval, EBL estimated blood loss, LHS length of hospital stay, OT operating time, PC postoperative complication, PN pelvic nodes, PR postoperative recurrence, OS overall survival, DFS disease-free survival, NA data are not available
aRandom effects model was used when the P for heterogeneity test < 0.05; otherwise, the fixed effect model was used
bP < 0.05 is considered statistically significant for Q test
cEgger’s test to evaluate publication bias, P < 0.05 is considered statistically significant

Comparison of robotic surgery and laparotomy

Six studies reported the variable EBL of the robotic surgery and laparotomy groups, and there was a significant heterogeneity between studies (P < 0.01, I2 = 93.9%). Similarly, there was a remarkable heterogeneity between studies for the variable OT (P < 0.01, I2 = 93.3%). Therefore, the random effects model was selected to assess the effect of EBL and OT. Meanwhile, no obvious heterogeneity was identified between studies for the variables OS rate, LHS, PC, PN, and PR, and the fixed effects model was selected.
The results of the pooled estimate for each variable are shown in Table 4, and it revealed that there was no statistical difference among the robotic surgery and laparotomy groups for the variables OT (WMD = 9.8527, 95% CI − 57.0904; 76.7958, P = 0.7730), PN (WMD = 0.0048, 95% CI − 1.9418; 1.9514, P = 0.9962), and PR (OR = 0.8506, 95% CI 0.3356; 2.1562, P = 0.7332), indicating that the robotic surgery and laparotomy in the treatment of ovarian cancer had similar effect on OT, PN, and PR. Only one study reported the variable DFS rate of the robotic surgery and laparotomy groups, and no statistical difference was found (data not shown). Meanwhile, there was a significant difference among the robotic surgery and laparotomy groups for the variables EBL (WMD = − 521.7027, 95% CI − 809.7816; − 233.6238, P = 0.0004), LHS (WMD = − 5.2225, 95% CI − 6.1485; − 4.2965, P < 0.0001), PC (OR = 0.4710, 95% CI 0.2537; 0.8747, P = 0.0171), and OS rate (OR = 6.4355, 95% CI 1.6722; 24.7678, P = 0.0070), presenting lesser EBL, shorter LHS, lower PC, and higher OS rate with robotic surgery treatment (Fig. 3).

Publication bias and sensitivity analysis

A significant publication bias (t = 6.8290, P = 0.002405) was identified for the variable PC in the robotic surgery and laparotomy groups, but no publication bias was identified for the other variables not only in the robotic surgery and laparotomy groups, but also in the robotic surgery and laparoscopy groups, suggesting the results of these indicators were reliable (Table 4).
Sensitivity analysis revealed that there was a difference between random effects model (P > 0.05) and fixed effects model (P < 0.05) for the pooled effect values of variables EBL and OT in the robotic surgery and laparoscopy groups. The pooled effect values of other variables based on random effects model and fixed effects model were consistent with each other, indicating that the results of those variables were stable (Table 5).
Table 5
Results of sensitivity analysis
Variable
Group
Effect model
K
WMD/OR [95% CI]
Z
P
Estimated blood loss
R vs. L
Fixed
5
− 39.9247 [− 78.7622; − 1.0871]
2.01
0.0439
R vs. L
Random
5
− 55.0871 [− 139.0087; 28.8345]
1.29
0.1983
R vs. O
Fixed
6
− 394.2279 [− 456.4271; − 332.0286]
12.42
< 0.0001
R vs. O
Random
6
− 521.7027 [− 809.7816; − 233.6238]
3.55
0.0004
Length of hospital stay
R vs. L
Fixed
5
− 0.7770 [− 1.7023; 0.1484]
1.65
0.0998
R vs. L
Random
5
− 1.4296 [− 3.5326; 0.6734]
1.33
0.1827
R vs. O
Fixed
6
− 5.2225 [− 6.1485; − 4.2965]
11.05
< 0.0001
R vs. O
Random
6
− 5.1505 [− 6.4793; − 3.8216]
7.60
< 0.0001
Operating time
R vs. L
Fixed
5
− 7.6177 [− 31.2545; 16.0192]
0.63
0.5276
R vs. L
Random
5
− 0.8561 [− 46.3735; 44.6612]
0.04
0.9706
R vs. O
Fixed
5
24.4862 [11.5380; 37.4344]
3.71
0.0002
R vs. O
Random
5
9.8527 [− 57.0904; 76.7958]
0.29
0.7730
Postoperative complication
R vs. L
Fixed
6
1.4541 [0.6502; 3.2516]
0.91
0.3619
R vs. L
Random
6
1.3484 [0.5235; 3.4731]
0.62
0.5357
R vs. O
Fixed
6
0.4710 [0.2537; 0.8747]
2.38
0.0171
R vs. O
Random
6
0.4878 [0.2600; 0.9154]
2.24
0.0254
Pelvic nodes
R vs. L
Fixed
3
− 0.5664 [− 3.1615; 2.0288]
0.43
0.6688
R vs. L
Random
3
− 0.2074 [− 3.5497; 3.1349]
0.12
0.9032
R vs. O
Fixed
4
0.0048 [−1.9418; 1.9514]
<0.01
0.9962
R vs. O
Random
4
0.0640 [− 2.5658; 2.6937]
0.05
0.9620
Postoperative recurrence
R vs. L
Fixed
2
0.2387 [0.0445; 1.2792]
1.67
0.0944
R vs. L
Random
2
0.2463 [0.0326; 1.8617]
1.36
0.1745
R vs. O
Fixed
2
0.8506 [0.3356; 2.1562]
0.34
0.7332
R vs. O
Randomed
2
0.7633 [0.1665; 3.4995]
0.35
0.7281
Overall survival rate
R vs. L
Fixed
2
2.2000 [0.0842;5 7.4835]
0.47
0.6360
R vs. L
Random
2
2.2000 [0.0842; 57.4835]
0.47
0.6360
R vs. O
Fixed
2
6.4355 [1.6722; 24.7678]
2.71
0.0070
R vs. O
Randomed
2
6.6854 [1.8172; 24.5959]
2.86
0.0040
Disease-free survival rate
R vs. L
Fixed
2
1.6909 [0.2572; 11.1175]
0.55
0.5850
R vs. L
Randomed
2
1.7085 [0.2641; 11.0547]
0.56
0.5740
K the number of articles included, R robot, L laparoscopic, O laparotomy, WMD weighted mean difference, OR odds ratio

Discussion

In the current study, the effect of robotic surgery in ovarian cancer therapy was compared with laparoscopy and laparotomy based on 647 patients recorded in eight studies. The results of the meta-analysis revealed that the robotic surgery and laparoscopy had the same effect in ovarian cancer therapy, while the robotic surgery had lesser EBL, shorter LHS, lower PC, and higher OR rate compared with laparotomy in ovarian cancer therapy.
Robotic system provided some merits, including 3-D visualization, ergonomic position, and eliminating hand tremor, promising a more accurate operation in various complex tumor surgery [9]. Reportedly, robotic surgery was viable in the staging for early ovarian cancer and had no obvious difference with laparoscopy in clinical outcomes including EBL, PC, and PN [23, 27]. Zapardiel et al. demonstrated that the robotic surgery presented similar outcomes of blood loss, PC, and LHS with laparoscopy in ovarian remnant syndrome therapy [28]. Moreover, a previous study had showed that the robotic surgery and laparoscopy were all safe and feasible for hepatectomies with no significant difference in surgical outcomes, except for the minimal incision of robotic surgery [29]. In accord with those views, our study revealed that robotic surgery provided a similar effect with laparoscopy in ovarian cancer therapy.
Compared with laparotomy, robotic surgery provided some advantages in the treatment of primary or recurrent ovarian cancer, including lesser EBL and shorter length of stay [30]. A previous study had reported it was advisable to select robotic surgery for the endometrial cancer staging than laparotomy surgical, with a decrease of hospital stay and EBL as well as PC rates and an increase of BMI [31]. Previous study had revealed that robotic surgery and laparoscopy presented a similar effect in radical hysterectomy and ovarian remnant syndrome and were more advisable versus laparotomy with a decrease of blood loss and hospital stay and PC [28, 32]. In addition, Subramaniam et al. proved that robotic surgery provided an improvement of surgical outcomes and might be a more advisable approach for obese women with endometrial cancer [33]. Those findings were all consistent with the results of our meta-analysis; hence, we indicated that robotic surgery was secure and feasible in ovarian cancer treatment and provided several merits than laparotomy.
Robotic surgery was considered as a promising new technique which could be used to optimize clinical management of patients with gynecological carcinoma. Nevertheless, concerns had been expressed focusing on the cost of robotic surgery compared to laparoscopy or laparotomy [34], and different opinions were proposed. Lindfors et al. suggested that there was no statistically significant difference in costs between robotic surgery and laparotomy in the treatment of elderly patients with endometrial cancer [35]. Novellis et al. indicated that the hospital could make a profit in spite of the high cost of robotic surgery [36]. A study reported that comparable outcomes were observed between robotic surgery and laparoscopy in the treatment for colon cancer, but robotic surgery showed higher treatment cost [37]. Besides, it was reported in two reviews that the high cost was mainly reflected in the acquisition, maintenance of instruments, and training of medical personnel using the robotic system [34, 38]. Further studies were recommended in the future to reduce the cost of robotic operations.
The heterogeneity test showed an obvious heterogeneity among studies for few variables, and we selected the random effect model to assess the pooled effect. Several reasons were considered as follows: (1) differences between different countries, race, and regions, such as China, Italy, and the USA; (2) differences among ovarian cancer with different types and stages, such as early stage of ovarian cancer, stage IA–IIIC epithelial ovarian cancer, recurrent ovarian cancer, and epithelial ovarian cancer; (3) influences from confounding factors such as gender, age, and other demographic data; (4) the same result might be interpreted differently by different authors, which might lead to a misleading result.
In this study, the meta-analysis was used to comprehensively compare the effect of robotic surgery in the treatment of ovarian cancer with laparotomy and laparoscopy, and we found that robotic surgery presented several merits in ovarian cancer therapy compared with laparotomy. But there still retained some limitations: (1) Subgroup analysis and meta-regression analysis for tumor stages, time of follow-up, age, and race were not performed due to the incomplete demographic data and less included studies. (2) There was a significant publication bias for the variable PC in the robotic surgery and laparotomy groups which might affect the result. In addition, the publication bias for the variable PR was not detected due to less included studies. (3) The result of sensitivity analysis showed that the pooled effect of the variables EBL (robotic surgery and laparoscopy groups) and OT (robotic surgery and laparotomy groups) was inconsistent under random or fixed effects models, which indicated the comparison results of the two variables were unstable. (4) Last but not the least, the related data were incomplete in the included studies, and only one study contained the related data of all the six variables, such as EBL, LHS, and OT were not mentioned in two studies; PN was not mentioned in four studies; PR and OS rate were not mentioned in five studies; and DFS rate was not mentioned in six studies. Besides, some of the data in several literatures were skewed, but these literatures also provide mean ± SD data which met the requirements of a meta-analysis, and they were included in this meta-analysis. Hence, an analysis based on more studies with high quality was needed to confirm the clinical effect of robotic surgery in ovarian cancer treatment.

Conclusions

In the current meta-analysis, the robotic surgery and laparoscopy presented the same effect in the treatment of ovarian cancer, while the robotic surgery provided lesser EBL, LHS, and PC and higher OS rate versus laparotomy. However, it failed to show oncological safety and recurrence by pathological stages or histologic types in this meta-analysis, and those confounding factors might affect the clinical outcome. Future meta-analyses with a larger number of eligible randomized controlled trial studies were needed to determine the most suitable treatment method for patients with different types and stages of ovarian cancer.

Acknowledgements

None.
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2015, 19:3–10.CrossRef Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2015, 19:3–10.CrossRef
2.
Zurück zum Zitat Slotman BJ, Rao BR. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res. 1988;8:417–34.PubMed Slotman BJ, Rao BR. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res. 1988;8:417–34.PubMed
3.
Zurück zum Zitat Liu Y, Du C, Liu W. New progress in ovarian cancer treatment. Modern Oncol. 2015;23:553–6. Liu Y, Du C, Liu W. New progress in ovarian cancer treatment. Modern Oncol. 2015;23:553–6.
4.
Zurück zum Zitat Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. Ca A Cancer J Clin. 2011;61:183–203.CrossRef Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. Ca A Cancer J Clin. 2011;61:183–203.CrossRef
6.
Zurück zum Zitat Ghezzi F, Cromi A. S, Bergamini V, Tomera S, Franchi M, Bolis P. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol Oncol. 2007;105:409–13.CrossRef Ghezzi F, Cromi A. S, Bergamini V, Tomera S, Franchi M, Bolis P. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol Oncol. 2007;105:409–13.CrossRef
7.
Zurück zum Zitat Childers JM, Lang J, Surwit EA, Hatch KD. Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol. 1995;59:25–33.CrossRef Childers JM, Lang J, Surwit EA, Hatch KD. Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol. 1995;59:25–33.CrossRef
8.
Zurück zum Zitat Chyi-Long L, Nari K, Hsiu-Lin C, Chih-Feng Y, Kuan-Gen H. The roles of laparoscopy in treating ovarian cancer. Taiwan J Obstet Gynecol. 2009;48:9–14.CrossRef Chyi-Long L, Nari K, Hsiu-Lin C, Chih-Feng Y, Kuan-Gen H. The roles of laparoscopy in treating ovarian cancer. Taiwan J Obstet Gynecol. 2009;48:9–14.CrossRef
9.
Zurück zum Zitat Anthony RL, Andres EC, Jaydev PD, William CM. Robotic surgery: a current perspective. Annals Surg. 2004;239:14–21.CrossRef Anthony RL, Andres EC, Jaydev PD, William CM. Robotic surgery: a current perspective. Annals Surg. 2004;239:14–21.CrossRef
10.
Zurück zum Zitat Ding X, Zhang T, Hou Q, Feng L, Chen L. A contrast analysis of robotic-assisted gynecological surgery, laparoscopy and open abdomen operation in the treatment of cervical cancer. Chin Clin Oncol. 2014;19:608–12. Ding X, Zhang T, Hou Q, Feng L, Chen L. A contrast analysis of robotic-assisted gynecological surgery, laparoscopy and open abdomen operation in the treatment of cervical cancer. Chin Clin Oncol. 2014;19:608–12.
11.
Zurück zum Zitat Marchal F, Rauch P, Vandromme J, Laurent I, Lobontiu A, Ahcel B, LV J, Meistelman C, Degueldre M, PV J. Telerobotic-assisted laparoscopic hysterectomy for benign and oncologic pathologies: initial clinical experience with 30 patients. Surg Endosc Other Interv Tech. 2005;19:826–31.CrossRef Marchal F, Rauch P, Vandromme J, Laurent I, Lobontiu A, Ahcel B, LV J, Meistelman C, Degueldre M, PV J. Telerobotic-assisted laparoscopic hysterectomy for benign and oncologic pathologies: initial clinical experience with 30 patients. Surg Endosc Other Interv Tech. 2005;19:826–31.CrossRef
12.
Zurück zum Zitat Mettler L, Schollmeyer T, Boggess J, Magrina JF, Oleszczuk A. Robotic assistance in gynecological oncology. Curr Opin Oncol. 2008;20:581.CrossRef Mettler L, Schollmeyer T, Boggess J, Magrina JF, Oleszczuk A. Robotic assistance in gynecological oncology. Curr Opin Oncol. 2008;20:581.CrossRef
13.
Zurück zum Zitat Moher D. Corrigendum to: Preferred Reporting Items For Systematic Reviews And Meta-Analyses: The PRISMA Statement International Journal of Surgery 2010; 8: 336-341. Int J Surg. 2010;8:658.CrossRef Moher D. Corrigendum to: Preferred Reporting Items For Systematic Reviews And Meta-Analyses: The PRISMA Statement International Journal of Surgery 2010; 8: 336-341. Int J Surg. 2010;8:658.CrossRef
14.
Zurück zum Zitat Slim K, Nini ED, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. Anz J Surg. 2015;73:712–6.CrossRef Slim K, Nini ED, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. Anz J Surg. 2015;73:712–6.CrossRef
15.
Zurück zum Zitat Liu T, Xu QE, Zhang CH, Zhang P. Occupational exposure to methylene chloride and risk of cancer: a meta-analysis. Cancer Causes Control. 2013;24:2037–49.CrossRef Liu T, Xu QE, Zhang CH, Zhang P. Occupational exposure to methylene chloride and risk of cancer: a meta-analysis. Cancer Causes Control. 2013;24:2037–49.CrossRef
16.
Zurück zum Zitat Lau J, Ioannidis J, Schmid C. Quantitative synthesis in systematic reviews. Annals Intern Med. 1997;127:820–6.CrossRef Lau J, Ioannidis J, Schmid C. Quantitative synthesis in systematic reviews. Annals Intern Med. 1997;127:820–6.CrossRef
17.
Zurück zum Zitat Huedo-Medina TB, Julio SM, Fulgencio MM, Juan B. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193.CrossRef Huedo-Medina TB, Julio SM, Fulgencio MM, Juan B. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193.CrossRef
18.
Zurück zum Zitat Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj Bri Med J. 1997;315:629.CrossRef Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj Bri Med J. 1997;315:629.CrossRef
19.
Zurück zum Zitat Bellia A, Vitale SG, Laganà AS, Cannone F, Houvenaeghel G, Rua S, Ladaique A, Jauffret C, Ettore G, Lambaudie E. Feasibility and surgical outcomes of conventional and robot-assisted laparoscopy for early-stage ovarian cancer: a retrospective, multicenter analysis. Arch Gynecol Obstet. 2016;294:1–8.CrossRef Bellia A, Vitale SG, Laganà AS, Cannone F, Houvenaeghel G, Rua S, Ladaique A, Jauffret C, Ettore G, Lambaudie E. Feasibility and surgical outcomes of conventional and robot-assisted laparoscopy for early-stage ovarian cancer: a retrospective, multicenter analysis. Arch Gynecol Obstet. 2016;294:1–8.CrossRef
20.
Zurück zum Zitat Chen CH, Chiu LH, Chen HH, Chan C, Liu WM. Comparison of robotic approach, laparoscopic approach and laparotomy in treating epithelial ovarian cancer. Int J Med Rob Comput Assisted Surg. 2016;12:268–75.CrossRef Chen CH, Chiu LH, Chen HH, Chan C, Liu WM. Comparison of robotic approach, laparoscopic approach and laparotomy in treating epithelial ovarian cancer. Int J Med Rob Comput Assisted Surg. 2016;12:268–75.CrossRef
21.
Zurück zum Zitat Chen HH, Chen CH, Liu WM. Comparison of robotics, laparoscopy and laparotomy in the management of recurrent ovarian cancer. J Minim Invasive Gynecol. 2015;22:S239–S39.PubMed Chen HH, Chen CH, Liu WM. Comparison of robotics, laparoscopy and laparotomy in the management of recurrent ovarian cancer. J Minim Invasive Gynecol. 2015;22:S239–S39.PubMed
22.
Zurück zum Zitat Feuer GA, Lakhi N, Barker J, Salmieri S, Burrell M. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach. Gynecol Oncol. 2013;131:520–4.CrossRef Feuer GA, Lakhi N, Barker J, Salmieri S, Burrell M. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach. Gynecol Oncol. 2013;131:520–4.CrossRef
23.
Zurück zum Zitat Gallotta V, Cicero C, Conte C, Vizzielli G, Petrillo M, Fagotti A, Chiantera V, Costantini B, Scambia G, Ferrandina G. Robotic versus laparoscopic staging for early ovarian cancer: a case-matched control study. J Minim Invasive Gynecol. 2017;24:293–8.CrossRef Gallotta V, Cicero C, Conte C, Vizzielli G, Petrillo M, Fagotti A, Chiantera V, Costantini B, Scambia G, Ferrandina G. Robotic versus laparoscopic staging for early ovarian cancer: a case-matched control study. J Minim Invasive Gynecol. 2017;24:293–8.CrossRef
24.
Zurück zum Zitat Magrina JF, Zanagnolo V, Noble BN, Kho RM, Magtibay P. Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy. Gynecol Oncol. 2011;121:100–5.CrossRef Magrina JF, Zanagnolo V, Noble BN, Kho RM, Magtibay P. Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy. Gynecol Oncol. 2011;121:100–5.CrossRef
25.
Zurück zum Zitat Magrina JF, Cetta RL, Chang YH, Guevara G, Magtibay PM. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol. 2013;129:336–40.CrossRef Magrina JF, Cetta RL, Chang YH, Guevara G, Magtibay PM. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol. 2013;129:336–40.CrossRef
26.
Zurück zum Zitat Ye MX, Yu L, Fan WS, Wang M, Bian LH, Gu CL, Zhao LY, Li LA, Meng YG. Clinical application of robotic plat form in the treatment of early ovarian cancer. Zhonghua Yi Xue Za Zhi. 2017;97:982.PubMed Ye MX, Yu L, Fan WS, Wang M, Bian LH, Gu CL, Zhao LY, Li LA, Meng YG. Clinical application of robotic plat form in the treatment of early ovarian cancer. Zhonghua Yi Xue Za Zhi. 2017;97:982.PubMed
27.
Zurück zum Zitat Brown JV, Mendivil AA, Abaid LN, Rettenmaier MA, Micha JP, Wabe MA, Goldstein BH. The safety and feasibility of robotic-assisted lymph node staging in early-stage ovarian cancer. Int J Gynecol Cancer. 2014;24:1493–8.CrossRef Brown JV, Mendivil AA, Abaid LN, Rettenmaier MA, Micha JP, Wabe MA, Goldstein BH. The safety and feasibility of robotic-assisted lymph node staging in early-stage ovarian cancer. Int J Gynecol Cancer. 2014;24:1493–8.CrossRef
28.
Zurück zum Zitat Zapardiel I, Zanagnolo V, Kho RM, Magrina JF, Magtibay PM. Ovarian remnant syndrome: comparison of laparotomy, laparoscopy and robotic surgery. Acta Obstetricia Et Gynecologica Scandinavica. 2012;91:965–9.CrossRef Zapardiel I, Zanagnolo V, Kho RM, Magrina JF, Magtibay PM. Ovarian remnant syndrome: comparison of laparotomy, laparoscopy and robotic surgery. Acta Obstetricia Et Gynecologica Scandinavica. 2012;91:965–9.CrossRef
29.
Zurück zum Zitat Allan T, Geller DA, Sukato DC, Shirin S, Samer T, Jennifer S, Wallis M, Reddy SK, Bartlett DL. Robotic versus laparoscopic hepatectomy: a matched comparison. Annals Surg. 2014;259:549–55.CrossRef Allan T, Geller DA, Sukato DC, Shirin S, Samer T, Jennifer S, Wallis M, Reddy SK, Bartlett DL. Robotic versus laparoscopic hepatectomy: a matched comparison. Annals Surg. 2014;259:549–55.CrossRef
30.
Zurück zum Zitat Lambrou N, Diaz R, Gatcliffe T, Gil L, Eisermann A. Robotic-assisted laparoscopy for primary or recurrent ovarian cancer: a comparison with laparotomy. Gynecol Oncol. 2012;125:S122–S22.CrossRef Lambrou N, Diaz R, Gatcliffe T, Gil L, Eisermann A. Robotic-assisted laparoscopy for primary or recurrent ovarian cancer: a comparison with laparotomy. Gynecol Oncol. 2012;125:S122–S22.CrossRef
31.
Zurück zum Zitat Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, Fowler WC. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol. 2008;199:360.e1–9.CrossRef Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, Fowler WC. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol. 2008;199:360.e1–9.CrossRef
32.
Zurück zum Zitat Magrina JF, Kho RM, Weaver AL, Montero RP, Magtibay PM. Robotic radical hysterectomy: comparison with laparoscopy and laparotomy. Gynecol Oncol. 2008;109:86–91.CrossRef Magrina JF, Kho RM, Weaver AL, Montero RP, Magtibay PM. Robotic radical hysterectomy: comparison with laparoscopy and laparotomy. Gynecol Oncol. 2008;109:86–91.CrossRef
33.
Zurück zum Zitat Subramaniam A, Kim KH, Bryant SA, Zhang B, Sikes C, Kimball KJ, Kilgore LC, Huh WK Jr. JMS, Alvarez RD. A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma. Gynecol Oncol. 2011;122:604–7.CrossRef Subramaniam A, Kim KH, Bryant SA, Zhang B, Sikes C, Kimball KJ, Kilgore LC, Huh WK Jr. JMS, Alvarez RD. A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma. Gynecol Oncol. 2011;122:604–7.CrossRef
34.
Zurück zum Zitat Iavazzo C, Gkegkes ID. Cost-benefit analysis of robotic surgery in gynaecological oncology. Best Pract Res Clin Obstet Gynaecol. 2017;45:7–18.CrossRef Iavazzo C, Gkegkes ID. Cost-benefit analysis of robotic surgery in gynaecological oncology. Best Pract Res Clin Obstet Gynaecol. 2017;45:7–18.CrossRef
35.
Zurück zum Zitat Lindfors A, Ãk Ã, Staf C, Sjã¶Li P, Sundfeldt K, Dahm-Kã¤Hler P. Robotic vs open surgery for endometrial cancer in elderly patients: surgical outcome, survival, and cost analysis. Int J Gynecol Cancer. 2018;28:692–9.CrossRef Lindfors A, Ãk Ã, Staf C, Sjã¶Li P, Sundfeldt K, Dahm-Kã¤Hler P. Robotic vs open surgery for endometrial cancer in elderly patients: surgical outcome, survival, and cost analysis. Int J Gynecol Cancer. 2018;28:692–9.CrossRef
36.
Zurück zum Zitat Novellis P, Bottoni E, Voulaz E, Cariboni U, Testori A, Bertolaccini L, Giordano L, Dieci E, Granato L, Vanni E, et al. Robotic surgery, video-assisted thoracic surgery, and open surgery for early stage lung cancer: comparison of costs and outcomes at a single institute. J Thorac Dis. 2018;10:790–8.CrossRef Novellis P, Bottoni E, Voulaz E, Cariboni U, Testori A, Bertolaccini L, Giordano L, Dieci E, Granato L, Vanni E, et al. Robotic surgery, video-assisted thoracic surgery, and open surgery for early stage lung cancer: comparison of costs and outcomes at a single institute. J Thorac Dis. 2018;10:790–8.CrossRef
37.
Zurück zum Zitat Chiu CC, Hsu WT, Choi JJ, Galm B, Lee MTG, Chang CN, Liu CYC, Lee CC. Comparison of outcome and cost between the open, laparoscopic, and robotic surgical treatments for colon cancer: a propensity score-matched analysis using nationwide hospital record database. Surg Endosc. 2019. https://doi.org/10.1007/s00464-019-06672-7. Chiu CC, Hsu WT, Choi JJ, Galm B, Lee MTG, Chang CN, Liu CYC, Lee CC. Comparison of outcome and cost between the open, laparoscopic, and robotic surgical treatments for colon cancer: a propensity score-matched analysis using nationwide hospital record database. Surg Endosc. 2019. https://​doi.​org/​10.​1007/​s00464-019-06672-7.
38.
Zurück zum Zitat Patel HRH, Ana L, Joseph JV. Robotic and laparoscopic surgery: cost and training. Surg Oncol. 2009;18:242–6.CrossRef Patel HRH, Ana L, Joseph JV. Robotic and laparoscopic surgery: cost and training. Surg Oncol. 2009;18:242–6.CrossRef
Metadaten
Titel
Comparison of efficacy of robotic surgery, laparoscopy, and laparotomy in the treatment of ovarian cancer: a meta-analysis
verfasst von
Can Shi
Yingchun Gao
Yijun Yang
Lei Zhang
Juanpeng Yu
Ting Zhang
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2019
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-019-1702-9

Weitere Artikel der Ausgabe 1/2019

World Journal of Surgical Oncology 1/2019 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.